NorDiag Extends License to Exact Sciences' Long-DNA Biomarker Tech | GenomeWeb
NEW YORK (GenomeWeb News) — Exact Sciences today said it has extended a licensing agreement for its long-DNA biomarker technology, called DIA, with NorDiag. 
Under the non-exclusive license, NorDiag will use the technology, which is designed to identify abnormal apoptosis at the molecular level, in its colorectal cancer-screening tests in Europe, Japan, and Australia.
The license also gives NorDiag the right to use the DIA marker to develop an in vitro diagnostic test kit.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Actress Jennifer Lopez is working with NBC on a CRISPR-inspired television show, according to the Hollywood Reporter.

Researchers trace the origin of one human papillomavirus lineage to Neanderthals or Denisovans, Vox reports.

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.